Skip to content

John Martin Corkery

6 papers in the library · 127 citations · publishing 2018-2026

Papers

Sort Most recent Most cited

Treatment and management approaches for ketamine misuse: A systematic review of medical interventions

Journal of Substance Use and Addiction Treatment July 1, 2026 Alessio Mosca, Stefania Chiappini, Andrea Miuli et al.

INTRODUCTION: Ketamine, initially developed as an anesthetic and now increasingly prescribed for treatment-resistant depression, is also widely misused in recreational contexts. Chronic ketamine use, often leading to dependence, has been associated with severe physical complications, including ulcerative cystitis and gastrointestinal dysfunction, as well as cognitive, affective, and psychotic...

Ketamine-Related Deaths Registered in Scotland 2013–2024

Clinical Neuropsychopharmacology and Addiction January 4, 2026 Amira Guirguis, John Martin Corkery, Fabrizio Schifano

Background: Ketamine, a dissociative anaesthetic and non-competitive NMDA receptor antagonist, has legitimate medical applications. However, rising illicit use across the United Kingdom (UK) has been accompanied by growing reports of toxicity, dependence, and deaths. These have led to renewed policy discussions. Rationale and Aim: Previous national studies have reported ketamine-related deaths...

Deaths related to the use of diarylethylamines, with a focus on the United Kingdom: A systematic review and case series report.

Journal of psychopharmacology (Oxford, England) July 1, 2025 John Martin Corkery, Caroline S Copeland, Fabrizio Schifano 2 citations

Diarylethylamine drugs possess dissociative properties. These emerged as drugs of misuse, with reports of strong addictive potential, high tolerance and compulsive intake. Since one of these drugs, diphenidine, was added to the 1971 Convention on Psychotropic Substances, the United Kingdom (UK) had to consider its control. The Advisory Council on the Misuse of Drugs 2023 advice included...

Drugs Used in "Chemsex"/Sexualized Drug Behaviour-Overview of the Related Clinical Psychopharmacological Issues.

Brain Sciences April 22, 2025 Fabrizio Schifano, Stefania Bonaccorso, Davide Arillotta et al. 14 citations

Background: "Chemsex" involves the intake of a range of drugs (e.g., synthetic cathinones, gamma-hydroxybutyric acid/gamma-butyrolactone (GHB/GBL), ketamine, methamphetamine, "poppers", type V phosphodiesterase (PDE) inhibitors, MDMA/ecstasy, cocaine, cannabis, and occasionally a few other molecules as well, to enhance and prolong sexual experiences. This paper aims to provide an overview of...

New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review.

Experimental Neurology May 1, 2021 Fabrizio Schifano, Stefania Chiappini, Andrea Miuli et al. 49 citations

The use of several new psychoactive substances (NPS) has become very popular and is posing global health risks. Chemically and pharmacologically diverse molecules are constantly emerging and are presenting with a wide range of clinical implications. Serotonin toxicity, and specifically Serotonin Syndrome (SS), might develop as a result of an over-activation of the serotoninergic system caused...

Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers.

Progress in Brain Research 2018 John Martin Corkery 62 citations

Ibogaine is an indole alkaloid found in the root bark of the Iboga shrub native to west Africa possessing hallucinogenic properties. For centuries it has been used in religious ceremonies and to gain spiritual enlightenment. However, since the early 1960s, its apparent ability to reduce craving for psychoactive substances including alcohol, cocaine, methamphetamine, opiates, and nicotine has...